Regulatory T cells: the future of autoimmune disease treatment. (3rd July 2019)

• Record Type: Journal Article
• Authors: Ryba-Stanisławowska, Monika; Sakowska, Justyna; Zieliński, Maciej; Ławrynowicz, Urszula; Trzonkowski, Piotr
• Is Part Of: Expert review of clinical immunology. Volume 15:Number 7(2019)
• Page Start: 777
• Page End: 789
• Publication Date: 2019-07-03
• Subjects: Tolerance -- regulatory T cells -- autoimmune diseases -- cell-based therapies -- clinical immunology -- biomarkers; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2019.1620602
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : CD4 + T regulatory cells (Tregs) have been described as the most potent immunosuppressive cells in the human body. They have been found to control autoimmunity, and clinical attempts have been made to apply them to treat autoimmune diseases. Some specific pathways utilized by Tregs in the regulation of immune response or Tregs directly as cellular products are tested in the clinic. Areas covered : Here, we present recent advances in the research on the biology and clinical applications of Tregs in the treatment of autoimmune diseases. Expert opinion : Regulatory T cells seem to be a promising tool for the treatment of autoimmune diseases. The development of both cell-based therapies and modern pharmacotherapies which affect Tregs may strongly improve the treatment of autoimmune disorders. Growing knowledge about Treg biology together with the latest biotechnology tools may give an opportunity for personalized therapies in these conditions.